RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 11.283

Change

+0.00 (+0.03)%

Market Cap

N/A

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-18 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.17 (-0.40%)

USD 0.95B
SOXS Direxion Daily Semiconductor B..

-1.03 (-4.10%)

USD 0.66B
PSQ ProShares Short QQQ

-0.28 (-0.72%)

USD 0.61B
SPXU ProShares UltraPro Short S&P50..

-0.25 (-1.09%)

USD 0.51B
SDOW ProShares UltraPro Short Dow30

+0.16 (+0.33%)

USD 0.29B
YANG Direxion Daily FTSE China Bear..

-4.59 (-5.70%)

USD 0.17B
SPDN Direxion Daily S&P 500® Bear ..

-0.04 (-0.36%)

USD 0.14B
RWM ProShares Short Russell2000

-0.04 (-0.22%)

USD 0.14B
DOG ProShares Short Dow30

+0.02 (+0.08%)

USD 0.13B
DUST Direxion Daily Gold Miners Ind..

-5.78 (-8.78%)

USD 0.10B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.42% 96% N/A 19% F
Dividend Return 3.50% 68% D+ 55% F
Total Return -1.93% 96% N/A 20% F
Trailing 12 Months  
Capital Gain -15.92% 93% A 10% F
Dividend Return 4.02% 58% F 52% F
Total Return -11.91% 93% A 11% F
Trailing 5 Years  
Capital Gain -70.32% 67% D+ 5% F
Dividend Return 2.66% 68% D+ 7% C-
Total Return -67.66% 67% D+ 5% F
Average Annual (5 Year Horizon)  
Capital Gain 61.60% 40% F 95% A
Dividend Return 62.66% 40% F 95% A
Total Return 1.06% 55% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 434.12% 62% D 3% F
Risk Adjusted Return 14.43% 45% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.